Clinical trials: Embryonal Neoplasm
Glioblastoma
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
BKM120 is a newly discovered drug that has been used in other research studies. Information from those other research studies suggests that BKM120 may help to slow or stop the growth of malignant gliomas.
- Trial name
- NCT01339052
- Testing
- BKM120, Surgery
- Where
- 7 sites in United States
- Volunteers
- 65 people
- Sponsor
- L. Nicolas Gonzalez Castro, MD, PhD
Glioblastoma Multiforme
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
This is a phase 2, multicenter study to determine the safety and efficacy of ICT-107 in treating a type of brain tumor called Glioblastoma Multiforme (GBM).
- Trial name
- NCT01280552
- Testing
- ICT-107
- Where
- 25 sites in United States
- Volunteers
- 124 people
- Sponsor
- Precision Life Sciences Group
Recurrent Melanoma, Stage IV Skin Melanoma
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
This randomized phase II trial is studying giving bevacizumab together with interferon alpha to see how well it works compared to giving bevacizumab alone in treating patients with metastatic malignant melanoma.
- Trial name
- NCT00026221
- Testing
- Recombinant Interferon Alfa, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00499616
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 189 sites in United States, Australia and 4 more
- Volunteers
- 464 people
- Sponsor
- Children's Oncology Group
Neuroendocrine Cancer
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
- Trial name
- NCT02318784
- Testing
- Carfilzomib
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- SCRI Development Innovations, LLC
Cancer
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
This was an open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination. This study was designed in four parts.
- Trial name
- NCT01072175
- Testing
- GSK2118436, GSK1120212
- Where
- 15 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide.
- Trial name
- NCT01026493
- Testing
- temozolomide 60 mg x 21 days, temozolomide 75 mg x 21 days, ABT-888 20 mg x 21 days
- Where
- 17 sites in United States
- Volunteers
- 257 people
- Sponsor
- Radiation Therapy Oncology Group
Extensive Stage Small Cell Lung Cancer
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1…
- Trial name
- DeLLphi-307 (NCT06502977)
- Testing
- Tarlatamab
- Where
- 12 sites in China
- Volunteers
- 32 people
- Sponsor
- Amgen
Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced)
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
This phase II trial studies how well giving dabrafenib alone and in combination with trametinib before surgery works in treating patients with advanced melanoma that can be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma
- Trial name
- NCT01701037
- Testing
- dabrafenib, trametinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Islet Cell Carcinoma, Neuroendocrine Carcinoma
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
The purpose of this study was to assess the efficacy and safety of everolimus in the treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic chemotherapy.
- Conditions
- Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms
- Trial name
- NCT00363051
- Testing
- Everolimus 10 mg, Octreotide Depot
- Where
- 54 sites in United States, Argentina and 9 more
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
This is a Phase 2 open-label, single-arm study of neoadjuvant treatment of intratumoral tavo-EP plus nivolumab IV infusion. Eligible participants will be those with pathological diagnosis of operable locally-regionally advanced…
- Trial name
- NCT04526730
- Testing
- Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma, Young Adult
Risk Information and Skin-cancer Education for Undergraduate Prevention
The purpose of this study will be to provide undergraduate students information about skin cancer risk and prevention. The study will last between 2-3 months.
- Trial name
- RISE-UP (NCT03979872)
- Testing
- MC1R Genetic Testing, Skin Cancer Education, UV Photo
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of Utah
Melanoma
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
This research study is evaluating a new type of melanoma vaccine called "Personalized NeoAntigen Cancer Vaccine". The purpose of this study is to determine if it is possible to make and administer safely a vaccine against…
- Trial name
- NCT01970358
- Testing
- Poly-ICLC, Peptides
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Patrick Ott, MD, PhD
Malignant Glioma, High Grade Glioma
Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of…
- Trial name
- ACTION (NCT03334305)
- Testing
- TTRNA-DC vaccines with GM-CSF, Dose-intensified TMZ, Autologous Hematopoietic Stem cells (HSCs)
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Florida
Childhood Germ Cell Tumor, Ovarian Cancer
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
RATIONALE: Germ cell tumors (GCT) are highly sensitive to chemotherapy such that even with metastatic disease at diagnosis, many patients can be cured.
- Conditions
- Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00432094
- Testing
- carboplatin, etoposide, ifosfamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has…
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension
- Trial name
- NCT01989572
- Testing
- Laboratory Biomarker Analysis, Sargramostim, Tyrosinase Peptide
- Where
- 148 sites in United States
- Volunteers
- 815 people
- Sponsor
- National Cancer Institute (NCI)
Glioma of Brain, Craniopharyngioma
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
Children with brain tumors who have had radiation therapy are at risk for problems with attention, memory, and problem solving. Such problems may cause difficulty in school and daily life.
- Conditions
- Glioma of Brain, Craniopharyngioma, Ependymoma, Germ Cell Tumor
- Trial name
- NCT03194906
- Testing
- Memantine, Cognitive Assessment
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- St. Jude Children's Research Hospital
Melanoma
Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma
Effective adjuvant treatment can increase cure in patients with high-risk resected melanoma. High dose interferon is a standard of care in the adjuvant setting but is highly toxic and marginally effective.
- Trial name
- NCT02656706
- Testing
- Ipilumumab, Nivolumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Brown University
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Carcinoid Tumors
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.
- Trial name
- NCT02795858
- Testing
- Ramucirumab, Somatostatin Analog
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Dana-Farber Cancer Institute